Abstract:

Background: Guyana, located on the northern South American Mainland is a moderate resource, developing country with high rates of traumatic hemorrhage. There is a shortage of blood products available for use in the emergency department of Georgetown Public Hospital, the main tertiary public hospital. Tranexamic acid (TXA) is an antifibrinolytic that inhibits both plasminogen activation and plasmin activity, thus preventing clot breakdown. CRASH-2, a large randomized, multicenter double blind, placebo-controlled clinical trial, that showed that TXA reduces mortality and blood product use in acute trauma in a moderate resource setting. Currently TXA is not available for use in the public health system in Guyana.

Methods: A literature review was conducted using Google Scholar and PubMed, and by analyzing review articles from the Cochrane Database, European Guidelines, NICE Guidelines. Sources were analyzed to determine pharmacology, feasibility and utility of TXA in moderate resource emergency medicine settings such as Guyana. Steps were taken to bring TXA for use in the public health system in Guyana.

Results: Meetings with stakeholders. Cost analysis. A protocol for initial utilization. Plan for data collection and future expansion.

Conclusions: Tranexamic acid is a safe and inexpensive drug that should be incorporated into trauma clinical guidelines for the resuscitation of the bleeding patient at Georgetown Public Hospital. Implementing a clinical guideline for the use of tranexamic acid in trauma at GPHC will improve mortality due to bleeding and reduce the use of blood products.

Keywords: Tranexamic acid; Acute trauma; Moderate resource setting.

References:

[1]. Health in the Americas, 2012 Edition: Country Volume N’ Pan American Health Organization, 2012. Available from: http://www.paho.org/saludenlasamericas/index.php?option=com_docman&task=doc_view&gi d=133&Itemid=

[2]. Guyana, Bureau of Statistics. Population & Housing Census 2012. Available from: http://www.statisticsguyana.gov. gy/census.html

[3]. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.

[4]. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006;60: S3– S11.

[5]. World Health Organisation: World Health Statistics 2009: Cause-specific mortality and morbidity. [http://www.who.int/whosis/whostat/ EN_WHS09_Table2.pdf].

[6]. Kashuk JL, Moore EE, Sawyer M, Wohlauer M, Pezold M, Barnett C, Biffl WL, Burlew CC, Johnson JL, Sauaia A. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg. 2010; 252:434Y442; discussion 443Y444.

[7]. Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Seminars in Hematology 2004;41(1 Suppl 1):55–64.

[8]. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003; 54:1127– 1130.

[9].  Sihler KC, Napolitano LM: Complications of massive transfusion. Chest 137:209-220, 2010.

[10]. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55: 39–44.

[11]. Fries D, Streif W, Haas T, Kuhbacher G. Dilutional coagulopathy, an underestimated problem? Anasthesiol Intensivmed Notfallmed Schmerzther 2004; 39: 745–50.

[12]. Gruen RL, Brohi K, Schreiber M, et al. Haemorrhage control in severely injured patients. Lancet. 2012; 380:1099–1108.

[13]. Hess John R, Brohi Karim, Dutton Richard P, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma. 2008; 65:748e754.

[14]. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008; 64: 1211–17.

[15]. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002; 28(Suppl. 2): S241–7.

[16]. Jansen JO, Scarpelini S, Pinto R, Tien HC, Callum J. Hypoperfusion in severely injured patients is associated with reduced coagulation factor activity. J Trauma. 2011 Nov;71(5 suppl 1): S435eS440.

[17]. Wolberg AS, Meng ZH, Monroe 3rd DM, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004 June;56(6):1221e1228.

[18]. Tsuei BJ, Kearney PA. Hypothermia in the trauma patient. Injury. 2004 Jan;35(1):7e15.

[19]. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5(Suppl 1):132Y142.

[20]. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003; 1:1487Y1494.

[21]. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012; 72:585Y617.

[22]. Lucas M, Fretto L, McKee P. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249–56.

[23]. http://www.drugbank.ca/drugs/DB00302.

[24]. http://www.ncbi.nlm.nih.gov/pubmed/3321402.

[25]. Pfizer. Cyklokapron (tranexamic acid) injection package insert. 2008. Available at: www.pfizer.com/products/rx/prescription.jsp. In.

[26]. Andrew P. Cap, MD, PhD, David G. Baer, PhD, Jean A. Orman, MPH, ScD, James Aden, PhD, Kathy Ryan, PhD, and Lorne H. Blackbourne, MD. Tranexamic Acid for Trauma Patients: A Critical Review of the Literature. DOI 101097TA0b013e31822114af.

[27]. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg. 1995; 110:835-842.

[28]. Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010; 18:132–138.

[29]. Henry DA, Moxey AJ, Carless PA, O’Connell D, Henderson KM, Fergusson D, et al. Anti- fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD001886.pub2].

[30]. Colman R, ed. Hemostasis and Thrombosis Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.

[31]. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376:23.

[32]. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377(9771):1096–101.

[33]. Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD004896. DOI:

[34]. 10.1002/14651858.CD004896.pub4.

[35]. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012; 147:113Y119.

[36]. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I: Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011, 6: e18987.

[37]. http://epmonthly.com/article/its-time-to-embrace-txa-for-traumatic-bleeds/.

[38]. Erik Nelson Vu, CCP, MD, FRCPC, DAvMed,1,2,3 Rob S. Schlamp, CCP,1 Robert T. Wand, CCP,1 Geoff A. Kleine-Deters, CCP, RN,1. Prehospital Use of Tranexamic Acid for Hemorrhagic Shock in Primary and Secondary Air Medical Evacuation. 1067-991X3600 Copyr 2013 Air Med J Assoc Httpdxdoiorg101016jamj201305001.

[39]. Brown JB, Neal MD, Guyette FX, Peitzman AB, Billiar TR, Zuckerbraun BS, et al. Design of the Study of Tranexamic Acid during Air Medical Prehospital Transport (STAAMP) Trial: Addressing the Knowledge Gaps. Prehosp Emerg Care. 2015 Jan 2;19(1):79–86.

[40]. Summary of the report of the 18th meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines, 18th Meeting, Accra, Ghana March 21Y25, 2011. Available a Accessed November 10, 2012.